Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 833 matching trials from the live ClinicalTrials.gov search.
Conditions
Hodgkin's Disease, Cervical Cancer, Breast Cancer, Lymphoma
Interventions
Telephone Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older · Female only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cervix Cancer
Interventions
Barrigel gel spacer
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
Interventions
Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment
Other · Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Results available

A Trial of Tisotumab Vedotin in Cervical Cancer

NCT03438396
Conditions
Cervical Cancer
Interventions
tisotumab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Conditions
Advanced Cancer
Interventions
FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
19
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Metastatic Cancer, Cervical Cancer
Interventions
Lorigerlimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Improving Compliance With Medical Testing Guidelines

NCT02430948
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colon Cancer, Lung Cancer
Interventions
Color-coded materials, Academic detailing, Standard support, No academic detailing
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
30 Years to 89 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Conditions
Cancer of the Cervix
Interventions
Cetuximab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
St Louis, Missouri • Charlottesville, Virginia
Conditions
Endometrial Carcinoma, Cervix Cancer, Carcinoma of the Uterus
Interventions
Radiation therapy
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Cervical Cancer
Interventions
Radiation Therapy, Cisplatin, Amifostine
Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
Interventions
VET3-TGI, Atezolizumab
Drug
Lead sponsor
KaliVir Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 4 more
Conditions
Cervical Cancer
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Terminated Phase 2 Interventional Results available

Pembrolizumab and Olaparib in Cervical Cancer Patients

NCT04483544
Conditions
Cervical Cancer, Cervical Carcinoma
Interventions
pembrolizumab, olaparib
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Miami, Florida • Plantation, Florida
Completed Early Phase 1 Interventional Results available

Gynecological Sentinel Lymph Nodes CEUS

NCT05105087
Conditions
Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Perflubutane Microbubble, Contrast-Enhanced Ultrasound
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced Solid Tumors
Interventions
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more
Conditions
Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Interventions
INCB099318
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee
Conditions
Cervical Cancer
Interventions
Nivolumab induction, Cisplatin, Radiation, Nivolumab with chemoradiation, Nivolumab maintenance
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Providence, Rhode Island
Recruiting Not applicable Interventional Accepts healthy volunteers

The Ohio State University (OSU) SCREEN Community Program

NCT06666192
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
Interventions
Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group, Health Care Delivery, Health Promotion, Health Promotion and Education, Health Risk Assessment, Implementation, Informational Intervention, Internet-Based Intervention, Interview, Outreach, Patient Navigation, Survey Administration
Other · Behavioral · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
2,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Cervical Cancer, Radiation Toxicity
Interventions
Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
17
States / cities
Jacksonville, Florida • Jacksonville Beach, Florida • Jascksonville, Florida + 11 more
Conditions
Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions
Educational Video and QPL List, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors

NCT01613430
Conditions
Colorectal Cancer, Breast Cancer, Cervical Cancer
Interventions
Coach Training (COACH), Printed Educational Materials (PEM)
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
50 Years to 74 Years
Enrollment
1,106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Honduras Liger Thermocoagulator Study

NCT03510273
Conditions
Cervix Cancer, Cervix Lesion
Interventions
Liger Medical Thermocoagulator
Device
Lead sponsor
PATH
Other
Eligibility
30 Years to 49 Years · Female only
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Solid Tumor
Interventions
ACTM-838
Drug
Lead sponsor
Actym Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania